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We evaluated the effect of subcutaneous teriparatide, 20 µg/day in a group of 16 postmenopausal pa-
tients with severe osteoporosis and multiple vertebral fractures.Vertebral (L1-L4) and femoral neck BMD
(g/cm2), plasma PTH (pg/ml), Osteocalcin (ng/ml) and Telopeptide (µg/l) levels were measured in all pa-
tients under control conditions. BMD values and plasma O and T levels were assessed again after 6
months of treatment. Pain was significantly reduced in all of the patients after 2 months of therapy. Verte-
bral BMD values were increase in all of the patients after 6 months from a basal value of 0.64±0.12
(mean±S.D.) to 0.66±0.09 g/cm2. Plasma T levels were significantly reduced from a basal values of
4.24±1.36 µg/l to 3.05±0.83 (p<0.01); plasma O levels increased from an average value of 7.10±2.33
ng/ml to a value of 11.10±3.86, but the increment did not reach statistical significance. Our data, obtained
in post-menopausal patients previously treated with bisphosphonates, indicate that teriparatide treatment
is able to increase vertebral BMD values after 6 months. The reduction of T values and the increase in O
levels indicates an active bone turnover in spite of the previous treatment with bisphosphonates. 
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